Bassiri-Tehrani Brian, Abi-Rafeh Jad, Baker Nusaiba F, Kerendi Alex N, Nahai Foad
Aesthet Surg J. 2023 Nov 16;43(12):1420-1428. doi: 10.1093/asj/sjad228.
Hematoma is the most common complication after facelift surgery. Hypertension is the major risk factor for hematoma following facelift. Measures taken to reduce systolic blood pressure perioperatively significantly reduce the risk of hematoma. There is evidence that treating systolic blood pressure of 140 mmHg or above reduces hematoma; there were no studies to date in which systolic blood pressures below 120 mmHg had been evaluated.
To assess the safety and efficacy of maintaining systolic blood pressures of 120 mmHg or less postoperatively to reduce hematoma after facelift.
A retrospective chart review of a single surgeon's series of facelift procedures from January 2004 to July 2018 was undertaken. Implementation of a more stringent perioperative blood pressure protocol (maintaining a systolic blood pressure of less than 120 mmHg postoperatively) was initiated in January of 2013, dividing patients into 2 groups.
A total of 502 consecutive patients who underwent a facelift by F.N. were included in the study. A total of 319 patients underwent a facelift before 2013, and a total of 183 patients underwent a facelift in 2013 or later. Overall, a total of 13 hematomas occurred during the entire 15-year study period (2.59%), of which 12 occurred before the implementation of a strict blood pressure regimen (3.76%), and only 1 occurred after the new protocol (0.5%). There were no adverse events related to the lower blood pressure.
Treating systolic blood pressure greater than 120 mmHg postoperatively is a safe and effective method for reducing the risk of hematoma after facelift.
血肿是面部提升手术后最常见的并发症。高血压是面部提升术后发生血肿的主要危险因素。围手术期采取措施降低收缩压可显著降低血肿风险。有证据表明,治疗收缩压140 mmHg及以上可降低血肿发生率;迄今为止,尚无研究评估收缩压低于120 mmHg的情况。
评估术后将收缩压维持在120 mmHg或更低以减少面部提升术后血肿的安全性和有效性。
对一位外科医生在2004年1月至2018年7月期间进行的一系列面部提升手术病例进行回顾性图表分析。2013年1月开始实施更严格的围手术期血压方案(术后将收缩压维持在低于120 mmHg),将患者分为两组。
本研究共纳入502例连续接受F.N.医生面部提升手术的患者。2013年之前共319例患者接受了面部提升手术,2013年及以后共183例患者接受了面部提升手术。总体而言,在整个15年的研究期间共发生13例血肿(2.59%),其中12例发生在严格血压方案实施之前(3.76%),新方案实施后仅发生1例(0.5%)。没有与较低血压相关的不良事件。
术后治疗收缩压大于120 mmHg是降低面部提升术后血肿风险的一种安全有效的方法。